ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2025
Total debt
$25.68M
Long-term debt
Net debt
-$386.00K
After $26.06M of cash
Implied interest rate
–
FY2024 interest ÷ average debt
Interest coverage
-20.5×
FY2024 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Adaptimmune Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.